Our journey
to revolutionize
medicine

Our Story

We began as a team of scientists building upon an established, yet not fully explored, way to approach disease: cellular stress and calcium imbalance in the cell.

Cellular stress and calcium imbalance have been shown to be at the root of a wide range of diseases. For years, we have been researching how activating a calcium pump called SERCA in the cell can restore calcium balance and reverse cellular stress.

Our breakthrough therapeutics are now under preclinical development for diseases such as diabetes, Alzheimer’s, Parkinson’s, Duchenne muscular dystrophy, and other rare diseases. We have formed impressive partnerships to help achieve our vision of changing the lives of patients suffering from debilitating diseases.

Leadership

Russell Dahl, Ph.D
CEO and Founder
Trained as a synthetic organic chemist, Dr. Russell Dahl has over 20 years of drug discovery experience having contributed to several successful INDs and NDAs. He has also founded and advised multiple startup companies developing therapeutics in diverse areas such as cancer, hearing loss, CNS disorders, and heart failure. Dr. Dahl has held tenure-track professor positions in medicinal chemistry and neuroscience and has co-authored over 100 publications. He is inventor on over 70 patents or applications in therapeutics and chemistry. He received his Ph.D. in Organic Chemistry from the University of California, San Diego as a DuPont Pharmaceuticals Fellow and received additional training in Molecular Pharmacology from Stanford.
Mike Young
Business Development
Mike has more than 30 years of experience as a vice president of worldwide marketing, sales, and business development for biotech companies with enabling technologies such as Genzyme and Decode Genetics. He studied biology at Canisius College, biochemistry at Nova University and medical sciences at Harvard University. He has worked with the NIH including establishing a collaboration with the NIAID to investigate the genetics of infectious diseases. Mike has been responsible for the business of biotech research tools, medical diagnostics, and pharmaceuticals in development, testing, and manufacture. These therapeutics include erythropoietin, Factor VIII, albumin, immune modulators, and oncology drugs with major pharma collaborators in the US, Europe, and Japan.
Brunde Broady
Board Member; Advisor, BD and Strategy
Brunde is a partner in a family-controlled venture firm. The firm maintains a long-term investment horizon and has funded several start-ups from its inception to upwards of $150 million-dollar valuation. Brunde is the author of the book “The Calcium Connection,” which covers the importance of Calcium ATPase, a key cellular enzyme that plays a pivotal role in health and disease. She earned her MBA at Yale University. Brunde has also invested in other biotech companies at various stages of development.
Frederick C. Beddingfield III, M.D., Ph.D.
Board Member
Dr. Frederick C. Beddingfield III is a physician-scientist and biotech entrepreneur. He is currently CEO and Board Director of Rubedo Life Sciences. He also serves as Co-Founder Chairman of the Board of Steelhead Bio and as a director of Cytrellis Biosystems. Previously, he was an Executive Partner at Apollo Health Ventures, a longevity and age-related disease fund. He served as CEO and director of Kira Pharmaceuticals developing biologics for immunology, inflammation, and rare diseases from 2020 to 2023. In 2016 he founded Sienna Biopharmaceuticals, Inc., served as President, Chief Executive Officer, and member of the board of directors and took the company public 18 months after its founding. Previously, he served as Chief Medical Officer of Kythera Biopharmaceuticals, acquired by Allergan in 2015 for $2.1B. Frederick worked at Allergan for 10 years (2003-2013) where he served in various roles, including the Therapeutic Area Head of Dermatology and Chief Medical Officer Allergan Medical. He has led the development and approvals of global leading brands in medical dermatology, aesthetics, neurology, metabolic, and other therapeutic areas. These brands include Botox (cosmetic, hyperhidrosis, spasticity, and others), Juvederm, Voluma, Kybella, Latisse, Aczone, and Tazorac. Frederick has led four FDA advisory committees, all succesful resultibg in approvals. Since completing his training, Frederick has maintained a clinical and teaching practice at UCLA. He is a board-certified dermatologist and emergency medicine physician and fellowship trained in dermatologic surgery and cutaneous oncology. Frederick completed his medical degree with honors at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the medical advisory board of the Children’s Skin Disease Foundation and Camp Wonder. He is on the board and co-founder of the Dermatology Summit and Dermatology Innovation Forum conferences, and a Board Trustee of Advancing Innovation in Dermatology, a non-profit organization.

Scientific Advisory Board

John Amatruda, M.D.
FMR Senior VP/Head of Diabetes & Obesity, Merck; Adjunct Professor of Medicine at Yale University School of MedicineYale University School of Medicine

John Amatruda, M.D. has over 25 years of experience as a senior pharmaceutical research executive and scientific consultant and over 40 years of experience in the practice and teaching of medicine. He currently sits on the board of directors and scientific advisory boards of several biotechnology companies. He has also been a consultant and scientific advisor to more than 20 additional biotechnology and leading pharmaceutical companies since 2009. Dr. Amatruda has co-authored over 160 publications in the areas of both clinical and basic research in diabetes, obesity and lipids, many of which have been published in leading peer-reviewed journals. Dr. Amatruda’s clinical practice at the University of Rochester and at Yale was in general endocrinology with an emphasis on Diabetes and Obesity. Dr. Amatruda received his formal education at Yale University and The Medical College of Wisconsin.

Carmella Evans-Molina, M.D., Ph.D.
Professor of Medicine; Director, Indiana Diabetes Research Center; Eli Lilly and Company Professor of Pediatric DiabetesIndiana University School of Medicine
Dr. Carmella Evans-Molina is the Eli Lilly Professor of Pediatric Diabetes at the IU School of Medicine, where she serves as director of the IU Center for Diabetes and Metabolic Diseases and the Herman B Wells Center for Pediatric Diabetes Research. Her research focuses on the molecular and inflammatory etiologies of beta cell dysfunction in diabetes mellitus with an emphasis on the regulation of intracellular calcium homeostasis. She has ongoing translational projects focused on the discovery and validation of novel serum biomarkers to identify early beta cell stress in clinically silent Type 1 diabetes. Recipient of the 2023 Outstanding Scientific Achievement Award, American Diabetes Association. Dr. Evans-Molina received her M.D. degree from Marshall University in Huntington, WV and her Ph.D. in Pharmacology from the University of Virginia.
Seth L. Robia, Ph.D.
Professor Department of Physiology Co-Director; Cardiovascular Research Institute; Stritch School of MedicineLoyola University Chicago Stritch School of Medicine

Seth L. Robia Ph.D. is a Professor in the Department of Cell and Molecular Physiology, Stritch School of Medicine, Loyola University Chicago and serves as Co-Director of the Loyola Cardiovascular Research Institute. His research focuses primarily on membrane transport proteins involved in cell signaling. He obtained his M.S. and Ph.D. degrees in Physiology at the University of Wisconsin-Madison and pursued postdoctoral research training at the University of Minnesota.

D. James Surmeier, Ph.D.
Chair, Department of Neuroscience; Nathan Smith Davis Professor of Neuroscience; Professor of NeuroscienceNorthwestern University Feinberg School of Medicine

D. James Surmeier Ph.D. is Nathan Smith Davis Professor and Chair of the Department of Neuroscience at the Feinberg School of Medicine at Northwestern University. His research program focuses on physiological determinants of Parkinson’s and Huntington’s diseases. Dr. Surmeier received his Ph.D. in Physiology and Biophysics from the University of Washington.

Twitter